Trial Profile
A Retrospective, single-center study of Idarucizumab for resumption of anticoagulation after dabigatran reversal
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Dec 2018
Price :
$35
*
At a glance
- Drugs Idarucizumab (Primary)
- Indications Blood coagulation disorders
- Focus Therapeutic Use
- 04 Dec 2018 New trial record
- 01 Nov 2018 Results published in the Journal of Thrombosis and Thrombolysis